title: Acquired EGFR Mutation as the Potential Resistance Driver to Crizotinib in a MET-Mutated Tumor.
authors: DITEP (Département d'Innovations Thérapeutiques et Essais Précoces), Gustave Roussy Cancer Campus, Villejuif, France.
authors: Marc-Antoine
authors: MA
authors: Benderra
authors: DITEP (Département d'Innovations Thérapeutiques et Essais Précoces), Gustave Roussy Cancer Campus, Villejuif, France.
authors: Sandrine
authors: S
authors: Aspeslagh
authors: DITEP (Département d'Innovations Thérapeutiques et Essais Précoces), Gustave Roussy Cancer Campus, Villejuif, France; Faculté de médicine Paris-Sud XI, Kremlin-Bicêtre, France; U981 INSERM, Gustave Roussy Cancer Campus, Villejuif, France.
authors: Sophie
authors: S
authors: Postel-Vinay
authors: U981 INSERM, Gustave Roussy Cancer Campus, Villejuif, France.
authors: Ludovic
authors: L
authors: Bigot
authors: Radiologie interventionnelle, Gustave Roussy Cancer Campus, Villejuif, France.
authors: Thierry
authors: T
authors: De Baere
authors: U981 INSERM, Gustave Roussy Cancer Campus, Villejuif, France; Département de Médecine Oncologique, Gustave Roussy Cancer Campus, Villejuif, France.
authors: Yohann
authors: Y
authors: Loriot
authors: Laboratoire de Recherche Translationnelle et Centre de Ressources Biologiques, AMMICA, INSERM US23/CNRS UMS3655, Gustave Roussy Cancer Campus, Villejuif, France; Département de Biologie et Pathologie Médicales, Gustave Roussy Cancer Campus, Villejuif, France.
authors: Ludovic
authors: L
authors: Lacroix
authors: DITEP (Département d'Innovations Thérapeutiques et Essais Précoces), Gustave Roussy Cancer Campus, Villejuif, France; Département de Médecine Oncologique, Gustave Roussy Cancer Campus, Villejuif, France.
authors: Christophe
authors: C
authors: Massard
authors: Direction de la recherche clinique, Gustave Roussy Cancer Campus, Villejuif, France.
authors: Gilles
authors: G
authors: Vassal
authors: Faculté de médicine Paris-Sud XI, Kremlin-Bicêtre, France; U981 INSERM, Gustave Roussy Cancer Campus, Villejuif, France.
authors: Fabrice
authors: F
authors: André
authors: DITEP (Département d'Innovations Thérapeutiques et Essais Précoces), Gustave Roussy Cancer Campus, Villejuif, France; Faculté de médicine Paris-Sud XI, Kremlin-Bicêtre, France; U981 INSERM, Gustave Roussy Cancer Campus, Villejuif, France. Electronic address: Jean-Charles.Soria@gustaveroussy.fr.
authors: Jean-Charles
authors: JC
authors: Soria
mesh_terms: D000230:Adenocarcinoma / Q000188:drug therapy* / Q000235:genetics; D000077192:Adenocarcinoma of Lung; D000077548:Anaplastic Lymphoma Kinase; D000077547:Crizotinib; D019008:Drug Resistance, Neoplasm; D066246:ErbB Receptors / Q000235:genetics*; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000235:genetics; D008875:Middle Aged; D009154:Mutation; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use*; D019859:Proto-Oncogene Proteins c-met / Q000235:genetics*; D011720:Pyrazoles / Q000627:therapeutic use*; D011725:Pyridines / Q000627:therapeutic use*; D020794:Receptor Protein-Tyrosine Kinases / Q000235:genetics
chemical_list: D047428:Protein Kinase Inhibitors; D011720:Pyrazoles; D011725:Pyridines; D000077547:Crizotinib; D000077548:Anaplastic Lymphoma Kinase; C512478:EGFR protein, human; D066246:ErbB Receptors; C491743:MET protein, human; D019859:Proto-Oncogene Proteins c-met; D020794:Receptor Protein-Tyrosine Kinases